Skip to main content

Allovir Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

KLRS$1.87-18.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Changes in Stockholders’ Equity

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
(in thousands, except share amounts) · Shares · Amount · Capital · Loss · Deficit · Equity
Balance at December 31, 202293,093,243$9$690,753$(468)$(465,775)$224,519
Stock-based compensation——10,029——10,029
Issuance of common stock, upon vesting of restricted stock334,747—————
Unrealized gain on available-for-sale securities———167—167
Net loss————(41,183)(41,183)
Balance at March 31, 202393,427,990$9$700,782$(301)$(506,958)$193,532
Stock-based compensation——10,288——10,288
Issuance of common stock, upon vesting of restricted stock179,092————-
Purchase of common stock under the 2020 Employee Stock Purchase Plan108,936—315——315
Issuance of common stock in public offering, net of underwriting discounts, commissions and offering costs20,000,000270,167——70,169
Unrealized gain on available-for-sale securities7676
Net loss————(45,267)(45,267)
Balance at June 30, 2023113,716,018$11$781,552$(225)$(552,225)$229,113
Stock-based compensation——10,468——10,468
Issuance of common stock, upon vesting of restricted stock250,576—————
Unrealized gain on available-for-sale securities———25—25
Net loss————(44,272)(44,272)
Balance at September 30, 2023113,966,594$11$792,020$(200)$(596,497)$195,334

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
(in thousands, except share amounts)SharesAmountCapitalLossDeficitEquity
Balance at December 31, 2023114,148,991$11$802,025$(62)$(656,193)145,781
Stock-based compensation——5,034——5,034
Issuance of common stock, upon vesting of restricted stock732,774—————
Unrealized loss on available-for-sale securities———(76)—(76)
Net loss————(30,299)(30,299)
Balance at March 31, 2024114,881,765$11$807,059$(138)$(686,492)$120,440
Stock-based compensation——5,908——5,908
Issuance of common stock, upon vesting of restricted stock394,309—————
Purchase of common stock under the 2020 Employee Stock Purchase Plan36,337—21——21
Unrealized loss on available-for-sale securities———(1)—(1)
Net loss————(6,076)(6,076)
Balance at June 30, 2024115,312,411$11$812,988$(139)$(692,568)$120,292
Stock-based compensation——4,947——4,947
Issuance of common stock, upon vesting of restricted stock125,708—————
Unrealized gain on available-for-sale securities———5—5
Net loss————(4,126)(4,126)
Balance at September 30, 2024115,438,119$11$817,935$(134)$(696,694)$121,118
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.